gimli

CORONA stock AI analysis

CORONA Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers

CORONA REMEDIES LIMITED is a small-cap stock in Healthcare. This Gimli page shows the latest available CORONA price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.

Analyze with AI Open interactive CORONA stock page

Price

₹2,201.80

1W return

+0.05%

1M return

+3.89%

3M return

+19.92%

6M return

+34.99%

1Y return

n/a

Market cap

₹n/a

n/a

ROE

+29.41%

ROCE

+14.09%

RSI

58.68

Turnover

₹2.67 cr

Why it can matter in screens

Momentum: CORONA is above 50DMA, below 200DMA; RSI is 58.68.
Returns: 1D +1.48%, 1W +0.05%, 1M +3.89%, 3M +19.92%, 1Y n/a.
Trend levels: 52W high ₹2,292.40, 52W low ₹1,658.10, off high -3.95%.
Liquidity: latest turnover is ₹2.67 cr; volume vs 20D is +0.23%.
Valuation/profitability: PE n/a, PB n/a, ROE +29.41%, ROCE +14.09%.
Growth: 3Y sales CAGR +16.67%, 3Y profit CAGR +29.65%.

Quick Answers

What is the latest CORONA stock price?

The latest stored price for CORONA is Rs 2,201.80 as of 2026-09-18.

Is CORONA above its 50DMA and 200DMA?

CORONA is above 50DMA, below 200DMA. The latest 50DMA is 2,104.58 and the latest 200DMA is n/a.

What are CORONA PE, ROE and ROCE?

CORONA has PE n/a, ROE +29.41%, and ROCE +14.09% in Gimli's latest available snapshot.

How has CORONA performed recently?

CORONA has returned +3.89% over 1 month, +19.92% over 3 months, and n/a over 12 months in the latest stored data.

Is this stock page investment advice?

No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.

Financials and Ownership

Quarterly income statement

Period	Revenue	EBITDA	PAT	EPS
2026-06-30	425.58 cr	96.28 cr	60.10 cr	9.83
2026-03-31	353.09 cr	66.41 cr	45.33 cr	7.41
2025-12-31	342.42 cr	66.32 cr	41.27 cr	6.75
2025-09-30	363.40 cr	80.74 cr	52.32 cr	8.55
2025-06-30	346.29 cr	71.00 cr	46.20 cr	7.55
2025-03-31	293.69 cr	55.85 cr	31.55 cr	5.16
2024-12-31	297.69 cr	70.36 cr	44.95 cr	7.35

Annual income statement

Year	Revenue	EBITDA	PAT	EPS
2026-03-31	1,403.18 cr	285.26 cr	185.12 cr	30.27
2025-03-31	1,196.42 cr	246.29 cr	149.43 cr	24.43
2024-03-31	1,013.68 cr	158.25 cr	90.50 cr	14.80
2023-03-31	883.53 cr	133.38 cr	84.93 cr	13.89
2022-03-31	623.93 cr	24.42 cr	-0.40 cr	-0.08

Balance sheet

Period	Assets	Cash	Debt	Equity
2026-03-31	1,205.14 cr	1.83 cr	164.85 cr	746.86 cr
2025-03-31	929.86 cr	3.22 cr	86.23 cr	606.34 cr
2024-03-31	830.58 cr	3.16 cr	158.96 cr	480.41 cr
2023-03-31	595.02 cr	14.49 cr	27.96 cr	408.52 cr

Cash flow

Period	OCF	FCF	Cash change
2026-03-31	229.48 cr	55.34 cr	n/a
2025-03-31	190.49 cr	98.83 cr	n/a
2024-03-31	156.76 cr	-129.58 cr	n/a
2023-03-31	102.70 cr	7.94 cr	n/a

Shareholding Trend

Period	Promoter	FII/FPI	DII	MF	Retail	Pledge
2026-06-30	+69.00%	+3.63%	+12.90%	+12.50%	+14.48%	+0.00%
2026-03-31	+69.00%	+2.25%	+7.02%	+6.35%	+21.74%	+0.00%
2025-12-31	+69.00%	+1.84%	+6.76%	+6.38%	+22.40%	+0.00%
2025-12-13	+69.00%	+1.04%	+3.65%	+2.44%	+26.32%	+0.00%

Industry Peers

Symbol	Name	Mcap	PE	ROE	1Y
SUNPHARMA	SUN PHARMACEUTICAL IND L	440,829.82 cr	36.388220	+15.50%	+11.45%
DIVISLAB	DIVI S LABORATORIES LTD	248,876.81 cr	85.407280	+18.37%	+53.39%
TORNTPHARM	TORRENT PHARMACEUTICALS L	163,807.57 cr	75.106636	+17.33%	+35.67%
APOLLOHOSP	APOLLO HOSPITALS ENTER. L	128,608.22 cr	65.670049	+21.03%	+13.94%
ZYDUSLIFE	ZYDUS LIFESCIENCES LTD	116,723.14 cr	26.011308	+16.04%	+10.70%
CIPLA	CIPLA LTD	112,647.78 cr	33.401961	+10.25%	-11.64%
LAURUSLABS	LAURUS LABS LIMITED	105,487.98 cr	96.587446	+21.77%	+111.64%
MAXHEALTH	MAX HEALTHCARE INS LTD	102,122.47 cr	70.799892	+14.33%	-10.58%

Try these prompts

Analyze CORONA REMEDIES with valuation, momentum and industry peers
Compare CORONA with other Healthcare stocks
Show small-cap stocks in Healthcare above 50DMA with positive 1M return
Find Healthcare stocks with improving momentum and reasonable valuation

Related screen ideas

Data snapshot: 2026-09-18. Not investment advice.